Dis Business was the largest of Quest Diagnostics Inc’s 2 reported lines in fiscal 2025, at $10.79B — 98% of $11.04B.
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dis Business | $9.61B | $8.98B | $9.61B | $10.79B | |||||||||||||
| Clinical Laboratory Testing Business | — | — | — | — | |||||||||||||
| Ds Businesses | $274.00M | $276.00M | $258.00M | $250.00M | |||||||||||||
| All Other Operating Segments | — | — | — | — | |||||||||||||
| Total | $9.88B | $9.25B | $9.87B | $11.04B |
In fiscal 2025, which ended December 31, 2025, the 2 segments Quest Diagnostics Inc reported in this breakdown added up to $11.04B. That was up 11.8% from $9.87B in fiscal 2024. Dis Business was the largest segment, at $10.79B or 97.7% of the total, followed by Ds Businesses ($250.00M, 2.3%).
Compared with fiscal 2024, Dis Business grew the fastest, rising 12.2% to $10.79B. Ds Businesses fell the most, down 3.1% to $250.00M. Over fiscal 2022 to 2025, revenue across these segments went from $9.88B to $11.04B, a compound annual growth rate of 3.7%. Dis Business' share of the total rose from 97.2% to 97.7% over the same years.
The table also keeps 2 segments that Quest Diagnostics Inc no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2009 to 2025, as reported in Quest Diagnostics Inc's annual filings.
Subsidiary Guarantors was the largest of Quest Diagnostics Inc’s 4 reported lines in fiscal 2009, at $6.14B — 82% of $7.46B.
| Legal Entity | FY 2008 | FY 2009 |
|---|---|---|
| Subsidiary Guarantors | $6.00B | $6.14B |
| Parent | $829.48M | $877.94M |
| Non-Guarantor Subsidiaries | $653.18M | $767.48M |
| Eliminations | -$232.77M | -$330.52M |
| Total | $7.25B | $7.46B |
In fiscal 2009, which ended December 31, 2009, the 4 revenue lines Quest Diagnostics Inc reported in this breakdown added up to $7.46B. That was up 2.8% from $7.25B in fiscal 2008. Subsidiary Guarantors was the largest revenue line, at $6.14B or 82.4% of the total, followed by Parent ($877.94M, 11.8%) and Non-Guarantor Subsidiaries ($767.48M, 10.3%). Together, the two largest revenue lines made up 94.1% of this total.
Compared with fiscal 2008, Non-Guarantor Subsidiaries grew the fastest, rising 17.5% to $767.48M. Every sizeable revenue line reported in both years grew.
Figures are shown as reported, so the total is net of Eliminations, which was -$330.52M in fiscal 2009. This breakdown covers every fiscal year from 2008 to 2009, as reported in Quest Diagnostics Inc's annual filings.
Routine Clinical Testing & Other Services was the largest of Quest Diagnostics Inc’s 4 reported lines in fiscal 2019, at $4.21B — 54% of $7.73B.
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|
| Routine Clinical Testing & Other Services | — | — | — | $4.21B | ||
| Routine Clinical Testing Services | $3.88B | $4.01B | $4.22B | — | ||
| Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services | $2.34B | $2.45B | $2.41B | $2.62B | ||
| Anatomic Pathology Testing Services | $624.00M | $612.00M | $578.00M | $579.00M | ||
| All Other Services | $377.00M | $335.00M | $327.00M | $321.00M | ||
| Total | $7.21B | $7.40B | $7.53B | $7.73B |
In fiscal 2019, which ended December 31, 2019, the 4 revenue lines Quest Diagnostics Inc reported in this breakdown added up to $7.73B. The revenue lines reported changed from fiscal 2018, so the total is not directly comparable with the $7.53B reported that year. Routine Clinical Testing & Other Services was the largest revenue line, at $4.21B or 54.4% of the total, followed by Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services ($2.62B, 33.9%) and Anatomic Pathology Testing Services ($579.00M, 7.5%). Together, the two largest revenue lines made up 88.4% of this total.
Compared with fiscal 2018, Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services grew the fastest, rising 8.8% to $2.62B. All Other Services fell the most, down 1.8% to $321.00M. Because revenue lines were added or dropped between the two years, part of this reflects how Quest Diagnostics Inc regrouped its reporting.
Routine Clinical Testing & Other Services was first reported as a separate revenue line in fiscal 2019. The table also keeps 1 revenue line that Quest Diagnostics Inc no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2014 to 2019, as reported in Quest Diagnostics Inc's annual filings.
Quest Diagnostics Inc (DGX) breaks its revenue down by segment and revenue line. In fiscal 2025, its largest segment was Dis Business, with $10.79B or 97.7% of the total, followed by Ds Businesses at $250.00M (2.3%).
Dis Business was Quest Diagnostics Inc's largest segment in fiscal 2025, with $10.79B in revenue, 97.7% of the $11.04B reported across its 2 segments.
Subsidiary Guarantors was Quest Diagnostics Inc's largest revenue line in fiscal 2009, with $6.14B in revenue, 82.4% of the $7.46B reported across its 4 revenue lines.
Of the Quest Diagnostics Inc segments reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Dis Business grew the fastest, rising 12.2% from $9.61B to $10.79B.
Every figure is taken from Quest Diagnostics Inc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2009 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.